![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NeoRx Presents Updated Data From Phase I Trial of STR in Breast Cancer
NeoRx Presents Updated Data From Phase I Trial of STR in Breast Cancer
NeoRx has announced the presentation of updated data from an investigator-sponsored Phase I Trial of STR, NeoRx's investigational bone-targeted radiotherapeutic, in patients with advanced breast cancer.
The Phase I dose-escalation study of STR involved six patients with Stage IV breast cancer metastasized to the bone. Patients were administered STR as a single agent followed by autologous blood stem-cell rescue. Two of the six patients remain alive, without progression of their disease up to six years post-transplant. Among the other four patients, the overall median time to disease progression was 10 months. Disease relapse in these four patients occurred in tissues outside the bone.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct